Boe Sorensen
0000-0002-9472-8099
Aarhus Universitet Health
85 papers found
Refreshing results…
The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
Post-cardiac arrest level of free-plasma DNA and DNA-histone complexes
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients
Exosomal proteins as prognostic biomarkers in non-small cell lung cancer
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib
Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer
Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers
Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1α down-regulation in metastatic cells
Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib
Abstract 5064: EGFR and HER3 are important in the interaction between lung cancer cells and fibroblasts
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
Missing publications? Search for publications with a matching author name.